Stock code：600380 Stock abbreviation：健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2021 Third Quarterly Report
Board of Directors (the “Board”) and all directors of the Company hereby warrant that there are no false
representations, misleading statements or material omissions contained in the third quarterly report (the “Report”),
and severally and jointly accept responsibility for the truthfulness, accuracy and completeness of the contents of
the Report.
IMPORTANT NOTICE:
The Board, the Supervisory Committee and the directors, supervisors and senior management of the
Company hereby warrant the truthfulness, accuracy and completeness of the contents of the Report,
and that there are no false representations, misleading statements or material omissions contained in
the Report, and severally and jointly accept responsibility.
The person-in-charge of the Company, the person-in-charge of the Company's accounting work and
the person-in-charge of the accounting department (the head of the accounting department) hereby
warrant the truthfulness, accuracy and completeness of the financial statements contained in the
Report.
Whether the third quarterly financial statements are audited
□Applicable √N/A
The Report is prepared in both Chinese and English. In case of any ambiguity in the understanding
of the Chinese and English texts, the Chinese version shall prevail.
I Principal Financial Data
(I) Principal accounting data and financial indicators
Unit: Yuan Currency: RMB
From the beginning
The Reporting of the year to the
Item Period Year-on-Year end of the Year-on-Year Change
(July-September Change (%) Reporting Period (%)
2021) (January –
September 2021)
Revenues 4,098,276,714.19 12.98 11,933,648,988.85 18.12
Net profit attributable to
Shareholders of the listed 321,327,690.20 27.91 1,008,675,184.73 8.76
company
Net profit attributable to
Shareholders of the listed
company after deducting 321,676,905.90 52.36 919,569,233.33 14.45
the extraordinary gain or
loss
Net cash flow from N/A N/A 1,621,169,704.58 -18.31
operating activities
Basic earnings per share 0.1640 25.67 0.5154 7.64
(RMB/share)
Diluted earnings per share 0.1638 26.49 0.5142 7.96
(RMB/share)
Weighted average return on 2.85 Increased by 0.47 8.89 Increased by 0.17
net assets (%) percentage point percentage point
End of the End of the Previous Year Change (%)
Reporting Period
Total assets 29,154,637,491.82 28,156,977,599.07 3.54
Owners’ equity attributable
to Shareholders of the listed 11,314,080,616.51 11,096,125,890.51 1.96
company
Note: 1. “Reporting Period” refers to the 3rd Quarter of 2021, from July 1, 2021 to September 30, 2021.
2. From January to September 2021, the Company recorded operating revenues of RMB 11,934
million, representing an increase of 18.12% year-on-year; the main driver of the growth is significant
increasing sales volume of main product categories in key specialist arenas of the Chemical drug
preparation segment. Revenues from chemical drug preparation products amounted to RMB 6,907
million, representing an increase of 40.96% year-on-year, of which, revenues from Inhalation products
amounted to 274 million, representing an increase of 957.88% year-on-year; Revenues from
anti-infective drugs amounted to RMB1,053 million, representing a decrease of 0.19% year-on-year;
Revenues from gastroenterology products amounted to RMB 2,993 million, representing an increase of
68.66% year-on-year; Revenues from gonadotropic hormones products amounted to RMB 1,978 million,
representing an increase of 37.75% year-on-year; Revenues from psychiatric products amounted to
RMB 306 million, representing an increase of 49.77% year-on-year. Revenues from APIs and
intermediates amounted to RMB 3,441 million, representing an increase of 17.51% year-on-year.
Revenues from traditional Chinese drug preparation produc
查看PDF原文
